financetom
Business
financetom
/
Business
/
Intuitive Surgical beats earnings estimates on strong demand for surgical robots
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intuitive Surgical beats earnings estimates on strong demand for surgical robots
Oct 21, 2025 1:56 PM

Oct 21 (Reuters) - Intuitive Surgical ( ISRG ) on

Tuesday reported better-than-expected third-quarter profit and

revenue, driven by growing demand for its surgical robots used

in minimally invasive procedures.

Shares of the Sunnyvale, California-based company surged 17%

in extended trading.

The company, known for its da Vinci robotic systems, has

seen steady growth as hospitals work through a backlog of

deferred procedures and expand access to minimally invasive

care.

The medical device maker slightly raised its adjusted gross

profit margin forecast for 2025 to between 67% and 67.5% from

between 66% and 67%.

The updated range includes an estimated impact from tariffs

of 0.7% of revenue, plus or minus 10 basis points, compared with

the previously estimated impact of 1% of revenue.

More than 80% of the instruments and accessories for the

company's da Vinci system are produced at Intuitive's facility

in Mexico, while the company also operates in China and other

international markets.

The company now expects worldwide da Vinci-assisted

procedures to increase about 17% to 17.5% in 2025, compared with

its previous range of 15.5% to 17%.

On an adjusted basis, the medical device maker earned $2.40

per share for the quarter ended September 30, beating analysts'

estimates of $1.98 per share, according to LSEG data.

The company reported revenue of $2.51 billion for the third

quarter, compared with analysts' estimates of $2.40 billion.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil

D'Silva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved